{
  "generated_at": "2026-02-05T21:07:06Z",
  "company_id": "jnj",
  "company_name": "Johnson & Johnson",
  "asset_count": 22,
  "change_count": 173,
  "assets": [
    {
      "asset_id": 1,
      "asset_name": "1-3PLs",
      "aliases": [
        "1-3PLs",
        "1-3PLs (MajesTEC-3)"
      ],
      "indications": [
        {
          "indication": "autoleucel) Myeloma Transplant Eligible vs intravesical delivery Bladder Cancer BCG-naïve (amivantamab) Cancer (ORIGAMI-5) Multiple Myeloma CD38 exposed",
          "stage": "Phase 2",
          "therapeutic_area": "Oncology",
          "as_of_date": null
        }
      ]
    },
    {
      "asset_id": 4,
      "asset_name": "Azacitidine",
      "aliases": [
        "Azacitidine",
        "Azacitidine (cAMeLot-2)",
        "Bleximenib",
        "Cusatuzumab",
        "JNJ-74494550",
        "JNJ-75276617",
        "Venetoclax"
      ],
      "indications": [
        {
          "indication": "Cancer (ATLAS) intravesical delivery system) Invasive Bladder Cancer BCG (ORIGAMI-2) Multiple Myeloma CD38 exposed with DR (MajesTEC-7)",
          "stage": "Registration",
          "therapeutic_area": "Oncology",
          "as_of_date": null
        }
      ]
    },
    {
      "asset_id": 3,
      "asset_name": "INLEXZO",
      "aliases": [
        "Cetrelimab",
        "Cisplatin",
        "gemcitabine",
        "INLEXZO",
        "INLEXZO (gemcitabine",
        "JNJ-17000139",
        "JNJ-42756493",
        "JNJ-63723283"
      ],
      "indications": [
        {
          "indication": "High Risk High Risk Non Muscle Experienced (SunRISe-5) RYBREVANT (amivantamab) Colorectal Cancer TALVEY + TECVAYLI Relapsed Refractory (MonumenTAL-6) TALVEY (talquetamab) TIE NDMM in combination",
          "stage": "Phase 3",
          "therapeutic_area": "Oncology",
          "as_of_date": null
        }
      ]
    },
    {
      "asset_id": 6,
      "asset_name": "JNJ-1493",
      "aliases": [
        "JNJ-1493"
      ],
      "indications": [
        {
          "indication": "Hematological",
          "stage": "Phase 1",
          "therapeutic_area": "Oncology",
          "as_of_date": null
        }
      ]
    },
    {
      "asset_id": 20,
      "asset_name": "JNJ-1887 sCD59",
      "aliases": [
        "JNJ-1887 sCD59"
      ],
      "indications": [
        {
          "indication": "Geographic Atrophy SPRAVATO (esketamine) Major Depressive Disorder Pediatrics",
          "stage": "Phase 3",
          "therapeutic_area": "Neuroscience",
          "as_of_date": null
        }
      ]
    },
    {
      "asset_id": 5,
      "asset_name": "JNJ-1900",
      "aliases": [
        "JNJ-1900",
        "JNJ-1900 (NBTXR3)",
        "JNJ-90301900",
        "NBTXR3"
      ],
      "indications": [
        {
          "indication": "Lung Cancer",
          "stage": "Phase 1",
          "therapeutic_area": "Oncology",
          "as_of_date": null
        }
      ]
    },
    {
      "asset_id": 11,
      "asset_name": "JNJ-2175",
      "aliases": [
        "JNJ-2175"
      ],
      "indications": [
        {
          "indication": "Solid Tumors",
          "stage": "Phase 3",
          "therapeutic_area": "Oncology",
          "as_of_date": null
        }
      ]
    },
    {
      "asset_id": 7,
      "asset_name": "JNJ-2761",
      "aliases": [
        "JNJ-2761"
      ],
      "indications": [
        {
          "indication": "Multiple Myeloma",
          "stage": "Phase 1",
          "therapeutic_area": "Oncology",
          "as_of_date": null
        }
      ]
    },
    {
      "asset_id": 12,
      "asset_name": "JNJ-3413",
      "aliases": [
        "JNJ-3413"
      ],
      "indications": [
        {
          "indication": "Lymphoma",
          "stage": "Phase 3",
          "therapeutic_area": "Oncology",
          "as_of_date": null
        }
      ]
    },
    {
      "asset_id": 8,
      "asset_name": "JNJ-4680",
      "aliases": [
        "JNJ-4680"
      ],
      "indications": [
        {
          "indication": "Lung Cancer",
          "stage": "Phase 1",
          "therapeutic_area": "Oncology",
          "as_of_date": null
        }
      ]
    },
    {
      "asset_id": 13,
      "asset_name": "JNJ-4681",
      "aliases": [
        "JNJ-4681"
      ],
      "indications": [
        {
          "indication": "Hematological Malignancies",
          "stage": "Phase 3",
          "therapeutic_area": "Oncology",
          "as_of_date": null
        }
      ]
    },
    {
      "asset_id": 16,
      "asset_name": "JNJ-4804 Co-antibody",
      "aliases": [
        "JNJ-4804 Co-antibody"
      ],
      "indications": [
        {
          "indication": "Psoriatic Arthritis nipocalimab​ Systemic Lupus",
          "stage": "Phase 1",
          "therapeutic_area": "Immunology",
          "as_of_date": null
        },
        {
          "indication": "Crohn's Disease nipocalimab​ Idiopathic Inflammatory",
          "stage": "Phase 3",
          "therapeutic_area": "Immunology",
          "as_of_date": null
        }
      ]
    },
    {
      "asset_id": 19,
      "asset_name": "JNJ-5120",
      "aliases": [
        "JNJ-5120"
      ],
      "indications": [
        {
          "indication": "Major Depressive",
          "stage": "Phase 1",
          "therapeutic_area": "Neuroscience",
          "as_of_date": null
        }
      ]
    },
    {
      "asset_id": 9,
      "asset_name": "JNJ-5322",
      "aliases": [
        "JNJ-5322"
      ],
      "indications": [
        {
          "indication": "Multiple Myeloma",
          "stage": "Phase 1",
          "therapeutic_area": "Oncology",
          "as_of_date": null
        }
      ]
    },
    {
      "asset_id": 14,
      "asset_name": "JNJ-7446",
      "aliases": [
        "JNJ-7446"
      ],
      "indications": [
        {
          "indication": "Lung Cancer",
          "stage": "Phase 3",
          "therapeutic_area": "Oncology",
          "as_of_date": null
        }
      ]
    },
    {
      "asset_id": 10,
      "asset_name": "JNJ-8377",
      "aliases": [
        "JNJ-8377"
      ],
      "indications": [
        {
          "indication": "Lymphoma",
          "stage": "Phase 1",
          "therapeutic_area": "Oncology",
          "as_of_date": null
        }
      ]
    },
    {
      "asset_id": 15,
      "asset_name": "JNJ-8543",
      "aliases": [
        "JNJ-8543"
      ],
      "indications": [
        {
          "indication": "Hematological Malignancies",
          "stage": "Phase 3",
          "therapeutic_area": "Oncology",
          "as_of_date": null
        }
      ]
    },
    {
      "asset_id": 22,
      "asset_name": "PulmonaryArterialH",
      "aliases": [
        "PulmonaryArterialH"
      ],
      "indications": [
        {
          "indication": "SIRTURO Leprosyunderreviewbyregulatorybodies.",
          "stage": "Phase 3",
          "therapeutic_area": null,
          "as_of_date": null
        }
      ]
    },
    {
      "asset_id": 2,
      "asset_name": "RYBREVANT",
      "aliases": [
        "5-fluorouracil",
        "amivantamab",
        "Carboplatin",
        "Cetuximab",
        "Co-Formulated",
        "Erbitux",
        "JNJ-61186372",
        "JNJ-73841937",
        "Lazertinib",
        "Levoleucovorin",
        "Pemetrexed",
        "RYBREVANT",
        "RYBREVANT (amivantamab)",
        "YH-25448",
        "YH25448"
      ],
      "indications": [
        {
          "indication": "Frontline Non Small chemotherapy (PAPILLON) Bleximenib Newly Diagnosed AML, with Venetoclax and ERLEADA (apalutamide) ASCT Localized Prostate",
          "stage": "Phase 3",
          "therapeutic_area": "Oncology",
          "as_of_date": null
        }
      ]
    },
    {
      "asset_id": 17,
      "asset_name": "Subcutaneous Induction",
      "aliases": [
        "ASTRO",
        "Bortezomib",
        "CNTO1959",
        "Daratumumab",
        "Dexamethasone",
        "Golimumab",
        "Guselkumab",
        "JNJ-64007957",
        "JNJ-78934804",
        "Lenalidomide",
        "Placebo",
        "Stelara",
        "Subcutaneous Induction",
        "Subcutaneous Induction (ASTRO)",
        "Talquetamab",
        "Teclistamab",
        "TREMFYA",
        "Ustekinumab",
        "Velcade"
      ],
      "indications": [
        {
          "indication": "(ICONIC-PsA)",
          "stage": "Phase 2",
          "therapeutic_area": "Immunology",
          "as_of_date": null
        }
      ]
    },
    {
      "asset_id": 21,
      "asset_name": "actorXla",
      "aliases": [],
      "indications": [
        {
          "indication": "i o n",
          "stage": "Phase 2",
          "therapeutic_area": null,
          "as_of_date": null
        }
      ]
    },
    {
      "asset_id": 18,
      "asset_name": "of the Fetus and Newborn",
      "aliases": [
        "AZALEA",
        "JNJ-80202135",
        "JNJ-86507083",
        "Nipocalimab",
        "of the Fetus and Newborn",
        "of the Fetus and Newborn (AZALEA)",
        "Placebo"
      ],
      "indications": [
        {
          "indication": "Colitis (QUASAR JR) Therapy",
          "stage": "Phase 2",
          "therapeutic_area": "Immunology",
          "as_of_date": null
        }
      ]
    }
  ]
}